Allelic frequencies of polymorphism c.521T>C (rs4149056) favor preemptive SLCO1B1 genotyping in Armenia
-
Stefan Németh
,
Hasmik Hayrapetyan
Abstract
Objectives
Statins represent an important pharmacological factor for the prevention of cardiovascular diseases but may also cause severe cases of myotoxicity. Numerous studies have described the association of the SLCO1B1 gene variant c.521C with statin-induced myopathy across different populations. This study aimed at evaluating the usefulness of preemptive SLCO1B1 genotyping in Armenia.
Methods
A total of 202 Armenian patients referred to the Center of Medical Genetics and Primary Health Care in Yerevan for upper respiratory tract infection between January and May 2022 were included in this study. Genotyping for SLCO1B1 c.521T>C (rs4149056) was performed using a commercially available real-time PCR assay (RealFast™).
Results
In total, 3/202 (1.5 %) samples were C/C homozygotes and 52/202 (25.7 %) were T/C heterozygotes, associated with a high and increased risk for statin-induced myopathy, respectively. The SLCO1B1 c.521C allelic frequency was 14.4 %.
Conclusions
The observed allele frequency of 14.4 % for the c.521C variant is slightly lower than frequencies reported from Europe, but relatively high compared to Asian populations, suggesting that preemptive SLCO1B1 genotyping could be a useful approach for the reduction of statin-induced adverse effects in Armenia.
-
Research ethics: The study was approved by the local Institutional Review Board (IRB), Center of Medical Genetics and Primary Healthcare, Yerevan, Armenia and is in accordance with the latest version of the Declaration of Helsinki.
-
Informed consent: All patients provided written informed consent.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: Authors state no conflict of interest.
-
Research funding: None declared.
-
Data availability: The raw data can be obtained on request from the corresponding author.
References
1. Baigent, C, Keech, A, Kearney, PM, Blackwell, PM, Buck, G, Pollicino, AK, et al.. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78. https://doi.org/10.1016/S0140-6736(05)67394-1.Search in Google Scholar PubMed
2. Hopewell, JC, Offer, A, Haynes, R, Bowman, L, Li, J, Bulbulia, R, et al.. Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. Eur Heart J 2020;41:3336–42. https://doi.org/10.1093/eurheartj/ehaa574.Search in Google Scholar PubMed PubMed Central
3. Thompson, PD, Clarkson, P, Karas, RH. Statin-associated myopathy. JAMA 2003;289:1681–90. https://doi.org/10.1001/jama.289.13.1681.Search in Google Scholar PubMed
4. Davila-Fajardo, CL, Diaz-Villamarin, X, Antunez-Rodriguez, A, Fernandez-Gomez, AE, Garcia-Navas, P, Martinez-Gonzalez, LJ, et al.. Pharmacogenetics in the treatment of Cardiovascular diseases and its current progress regarding implementation in the clinical routine. Genes 2019;10:261. https://doi.org/10.3390/genes10040261.Search in Google Scholar PubMed PubMed Central
5. Goljan, E, Abouelhoda, M, Tahir, A, ElKalioby, M, Meyer, B, Monies, D. Large-scale next generation sequencing based analysis of SLCO1B1 pharmacogenetics variants in the Saudi population. Hum Genom 2024;18:30. https://doi.org/10.1186/s40246-024-00594-9.Search in Google Scholar PubMed PubMed Central
6. Ramsey, LB, Johnson, SG, Caudle, KE, Haidar, CE, Voora, D, Wilke, RA, et al.. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther 2014;96:423–8. https://doi.org/10.1038/clpt.2014.125.Search in Google Scholar PubMed PubMed Central
7. Kim, SR, Saito, Y, Sai, K, Kurose, K, Maekawa, K, Kaniwa, N, et al.. Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15. Drug Metabol Pharmacokinet 2007;22:456–61. https://doi.org/10.2133/dmpk.22.456.Search in Google Scholar PubMed
8. Pasanen, MK, Neuvonen, PJ, Niemi, M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 2008;9:19–33. https://doi.org/10.2217/14622416.9.1.19.Search in Google Scholar PubMed
9. Xiang, Q, Chen, SQ, Ma, LY, Hu, K, Zhang, Z, Mu, GY, et al.. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J 2018;18:721–9. https://doi.org/10.1038/s41397-018-0054-0.Search in Google Scholar PubMed
10. Xiang, Q, Zhang, XD, Mu, GY, Wang, Z, Liu, ZY, Xie, QF, et al.. Correlation between single-nucleotide polymorphisms and statin-induced myopathy: a mixed-effects model meta-analysis. Eur J Clin Pharmacol 2021;77:569–81. https://doi.org/10.1007/s00228-020-03029-1.Search in Google Scholar PubMed
11. Cooper-DeHoff, RM, Niemi, M, Ramsey, LB, Luzum, JA, Tarkiainen, EK, Straka, RJ, et al.. The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated mucoskeletal symptoms. Clin Pharmacol Ther 2022;111:1007–21. https://doi.org/10.1002/cpt.2557.Search in Google Scholar PubMed PubMed Central
12. Nguyen, KA, Li, L, Lu, D, Yazdanparast, A, Wang, L, Kreutz, RP, et al.. A comprehensive review and meta-analysis of risk factors for statin-induced myopathy. Eur J Clin Pharmacol 2018;74:1099–109. https://doi.org/10.1007/s00228-018-2482-9.Search in Google Scholar PubMed
13. Vassy, JL, Gaziano, JM, Green, RC, Ferguson, RE, Avandi, S, Miller, SJ, et al.. Effect of pharmacogenetic testing for statin myopathy risk vs usual Care on blood cholesterol: a randomized clinical trial. JAMA Netw Open 2020;3:e2027092. https://doi.org/10.1001/jamanetworkopen.2020.27092.Search in Google Scholar PubMed PubMed Central
© 2024 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Review
- The potential antibacterial effects of tea polyphenols
- Original Articles
- Bottom-up PBPK modeling of phenytoin brain disposition in postpartum newborns after intrauterine dosing
- Molecular pathogenesis of microsatellite instability-high early-stage colorectal adenocarcinoma in India
- Effect of a polyherbal Unani formulation on left ventricular diastolic dysfunction in hypertensive patients – a randomized single blind placebo controlled clinical trial
- Acute and sub-chronic oral GLP toxicity of Withania somnifera root extract in Sprague Dawley rats
- Short Communication
- Allelic frequencies of polymorphism c.521T>C (rs4149056) favor preemptive SLCO1B1 genotyping in Armenia
Articles in the same Issue
- Frontmatter
- Review
- The potential antibacterial effects of tea polyphenols
- Original Articles
- Bottom-up PBPK modeling of phenytoin brain disposition in postpartum newborns after intrauterine dosing
- Molecular pathogenesis of microsatellite instability-high early-stage colorectal adenocarcinoma in India
- Effect of a polyherbal Unani formulation on left ventricular diastolic dysfunction in hypertensive patients – a randomized single blind placebo controlled clinical trial
- Acute and sub-chronic oral GLP toxicity of Withania somnifera root extract in Sprague Dawley rats
- Short Communication
- Allelic frequencies of polymorphism c.521T>C (rs4149056) favor preemptive SLCO1B1 genotyping in Armenia
